ADC 수탁제조 시장(제7판) : 개발 단계별, 프로세스 컴포넌트별, 페이로드별, 항체 아이소타입별, 표적 적응증별, 항체 유래별, 링커별, 주요 지역별 - 업계 동향과 세계 예측(-2035년)

ADC Contract Manufacturing Market: Overview

As per Roots Analysis, the ADC contract manufacturing market is estimated to grow from USD USD 1,720 million in 2025 in the current year to USD 3,212 million by 2035 at a CAGR of 6.4% during the forecast period, till 2035.

Scale of Operation

• Clinical Scale
• Commercial Scale

Process Component

• Tubulin Inhibitors
• Topoisomerase Inhibitors
• DNA Damaging Agents
• Others

Type of Payload

• Tubulin Inhibitors
• Topoisomerase Inhibitors
• DNA Damaging Agents
• Others

Antibody Isotype

• IgG1
• IgG4
• Others

Target Indication

• Solid Tumors
• Hematological Malignancies

Type of Linker

• Valine-citrulline
• SMCC
• Hydrazone
• Maleimide
• Maleimidocaproyl
• Tetrapeptide-based linker
• Peptide Linker
• Others

Antibody Origin

• Humanized
• Chimeric
• Human
• Others

Key Geographical Regions

• North America
• US
• Canada
• Rest of North America
• Europe
• UK
• Spain
• Italy
• Germany
• France
• Rest of Europe
• Asia-Pacific and Rest of the World
• China
• Japan
• India
• South Korea
• Australia
• Argentina
• Brazil
• Chile
• Columbia
• Israel
• Kenya
• Peru
• South Africa
• Turkey
• Saudi Arabia
• Rest of Asia-Pacific and rest of the world

ADC Contract Manufacturing Market: Growth and Trends

Antibody drug conjugates (ADCs) have shown remarkable promise in recent years for the treatment of various cancers, encompassing both solid tumors and hematological malignancies. These intricate molecules, consisting of an antibody linked to biologically active, cytotoxic substances via chemical connectors, demonstrate improved stability, target specificity, tumor selectivity, and pharmacokinetic characteristics.

At present, the ADC pipeline comprises more than 614 drug candidates in clinical trial assessment, in addition to 28 ADC therapeutic programs that have received approval from different regulatory bodies. The production process for ADC necessitates specialized knowledge and the application of advanced technologies, both of which are cost intensive. Consequently, ADC developers favor delegating manufacturing tasks to ADC contract manufacturers. By utilizing the expertise, resources, and production facilities of these CMOs, developers can streamline costs and speed up schedules. Due to the rising demand for ADCs and the growing tendency for drug developers to outsource operations, the ADC contract manufacturing market is expected to experience significant growth throughout the forecast period.

ADC Contract Manufacturing Market: Key Insights

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• The current market landscape features a presence of close to 35 companies that claim to have the required capabilities to offer contract manufacturing and conjugation services for antibody drug conjugates, worldwide.
• Majority (~65%) of the manufacturers offer different types of services across all scales of operation, in order to become one-stop shops for mitigating technical challenges such as technology transfer and scale-up for clients.

• Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the ADC contract manufacturing domain.
• Industry players are undertaking significant efforts to strengthen their infrastructure and enhance service offerings in this domain, with most of the initiatives undertaken in the last 12 months.
• The rising interest in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 60% of the deals were inked in the last three years.

• More than 780 clinical trials have been registered till date to evaluate the safety and efficacy of various antibody drug conjugates; majority of these studies have been conducted across various sites in the US.
• Various ADC therapeutic developers are anticipated to forge strategic alliances with contract manufacturing service providers in order to outsource complex manufacturing operations.
• The deployment of ADCs requires the selection of antibody, linker, and cytotoxic payload, in order to target high-expression tumor antigens that are internalized by the cell.
• Notably, over 30% of the total capacity expansion initiatives were carried out by the players located in North America, reflecting the region's dominance in advanced ADC manufacturing infrastructure.
• The global installed antibody drug conjugates manufacturing capacity is well distributed across various geographies; interestingly, around 90% of total installed capacity is available in facilities owned by large players.
• The demand for ADC therapeutics is likely to increase significantly as several clinical candidates are expected to be commercialized across various regions.
• Driven by the expanding pipeline of ADC therapeutics and manufacturing expertise available with contract service providers, the ADC contract manufacturing market is poised to witness significant growth in the future.

• Europe currently dominates the market (45%) and captures the largest share within the ADC contract manufacturing market; this is followed by North America.
• The humanized sub-segment is estimated to capture majority of the overall market share in the current year, owing to its enhanced safety and reduced immunogenicity.
• The ADC contract manufacturing market in North America is expected to capture maximum share by 2035; further, close to 85% of the companies in this domain offer services for antibody manufacturing.

ADC Contract Manufacturing Market: Key Segments

Commercial Scale of Operation Accounts for the Largest Share of ADC Contract Manufacturing Market

In terms of scale of operation, the ADC contract manufacturing market is segmented across various scales of operation such as clinical and commercial scale. Currently, the commercial scale segment occupies the higher market share (around 90%), owing to the surging demand for ADCs as potent targeted cancer therapies. The clinical segment is likely to grow at a higher CAGR (7.6%) during the forecast period. This stems from many ADC drug candidates authorized by regulatory agencies since 2021. Advancements in ADC therapies have led to a growing quantity of ADCs moving into the clinical development phase.

Solid Tumors Segment to Hold the Highest Revenue in the ADC Contract Manufacturing Market

In the current year, solid tumors segment is likely to capture majority of the ADC contract manufacturing market size (with a share of 80%), and this trend is unlikely to change in the future as well. This prevalence arises from the fact that the majority of commercialized ADC therapeutics and those in advanced clinical trials specifically for solid tumors. The market for hematologic cancers is expected to expand at a CAGR of 8.7% during the forecast period.

Antibodies are Likely to Hold the Highest ADC Contract Manufacturing Market Share in the Future

In the current year, the antibody segment occupies the highest share in the overall market and this trend is expected to remain same during the forecast period. The higher share of antibodies is due to the complex cellular or protein engineering requirements, making antibody manufacturing a time and cost-intensive process, thus prompting the need for more specialized antibody manufacturing expertise.

Asia-Pacific is Likely to Propel the ADC Contract Manufacturing Market

The market in Asia-Pacific and rest of the world is likely to grow at a relatively higher CAGR (8.5%), during the forecast period. This is a result of significant cost advantage offered by this region, particularly in countries such as China and India, where lower labor costs and operational expenses provide favorable manufacturing environment as compared to traditional hubs in North America and Europe. Examples of ADC contract manufacturing companies based in Asia-Pacific include Shilpa Biologics, WuXi Biologics, Formosa Laboratories, Syngene and Samsung Biologics.

Example Players in the ADC Contract Manufacturing Market

• AbbVie Contract Manufacturing
• Abzena
• CARBOGEN AMCIS
• Catalent Pharma Solutions
• Cerbios-Pharma
• MabPlex
• Millipore Sigma
• Lonza
• WuXi Biologics

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

• Senior Director, Commercial Development, Large company, Europe
• Business Development Manager, Mid-sized company, Europe
• Chief Executive Officer, Large company, Europe
• Chief Executive Officer and Founder, Small Company, UK
• Chief Executive Officer and Co-Founder, Small Company, France
• Former Chief Executive Officer, Large Company, US
• Chief Commercial Officer, Mid-sized Company, Switzerland
• Chief Business Officer, Small Company, Switzerland
• Executive Director, Large Company, Japan and Chief Innovation Officer, Large Company, Japan
• Director, Business Development, Small Company, Netherlands
• Director Corporate Development, Mid-sized Company, US
• Director, Business Development, Large Company, US and Former Group Product Manager, Large Company, US
• Former Director of CDMO, Large Organization, France
• Business Development Manager, Mid-sized Company, Switzerland
• Former Head of Bioconjugates Commercial Development, Large Company, Switzerland
• Former Site Head, Large Company, US
• Associate Scientist, Large Company, US

ADC Contract Manufacturing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the ADC contract manufacturing market, focusing on key market segments, including [A] stage of development, [B] process component, [C] type of payload, [D] antibody isotype, [E] target indication, [F] antibody origin, [G] type of linker and [H] key geographical regions.
• Market Landscape: A comprehensive evaluation of overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of ADC manufacturing service offered, [E] type of additional service offered, [F] scale of and [G] location of manufacturing facility.
• Company Profiles: In-depth profiles of companies engaged in the manufacturing of ADCs headquartered in North America, Europe and Asia-Pacific focusing on [A] company overview, [B] ADC contract manufacturing portfolio, [C] recent developments and [D] an informed future outlook.
• Company Competitiveness Analysis: A comprehensive competitive analysis of ADC contract manufacturers, examining factors, such as [A] supplier strength, [B] service strength and [C] number of manufacturing facilities.
• Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders in the ADC contract manufacturing market based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C], year and type of partnership and [D], geographical distribution of partnership activity.
• Recent Expansions: A detailed analysis of the recent expansions undertaken by various ADC contract manufacturers, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] type of excipient, [D] type of expansion (region and country), [E] location of expanded facility (region), [F] location of expanded facility (country), [G] most active players (in terms of number of recent expansions) and [H] geographical distribution (region and country).
• Capacity Analysis: An estimate of the global installed capacity for antibody contract manufacturing taking into consideration the capacities of various ADC contract manufacturers, based on several relevant parameters, such as [A] company size, [B] scale of operation and [C] key geographical regions.
• Make Versus Buy Decision Making: A detailed evaluation of current and future opportunity within the ADC contract manufacturing market across different process components, such as [A] antibody, [B] HPAPI / cytotoxic payload, [C] conjugation / linker and [D] fill / finish.
• Value Chain Analysis: A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
• Case Study: An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as [A] status of development, [B] target disease indication, [C] therapeutic area, [D] line of treatment, [E] dosing frequency, [F] type of therapy, [G] target antigen, [H] antibody isotype, [I] payload / cytotoxin / warhead, [J] type of payload and [K] type of linker.
• Clinical Trial Analysis: An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] target patient population, [F] patient gender, [G] type of sponsor / collaborator, [H] study design, [I] most active player (based on the number of registered trials) and [J] geography.
• Likely Partners Analysis: An in-depth analysis of ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as [A] developer strength, [B] pipeline strength and [C] maturity and [D] manufacturing capabilities.
• Demand Analysis: An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength of approved products and [D] clinical stage candidates.
• Regional Capability Analysis: A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the [A] number of ADC contract manufacturers, [B] number of ADC manufacturing facilities, [C] number of facility expansions, [D] installed ADC bioconjugation capacity, [E] number of registered clinical trials and [F] demand for ADCs in that particular geographical region.
• Attractiveness Competitiveness Matrix: A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
• Market Impact Analysis: In-depth analysis of the factors that can impact the growth of the ADC contract manufacturing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Value and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product (GDP)
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross-Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Key Components of ADCs
  • 6.2.1. Antibody
  • 6.2.2. Cytotoxin (Payloads)
  • 6.2.3. Linker
• 6.3. ADC Manufacturing
  • 6.3.1. Key Steps
  • 6.3.2. Technical Challenges
  • 6.3.3. Need for Outsourcing
• 6.4. Challenges Associated with Supply Chain and Method Transfer
  • 6.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
• 6.5. Selecting a CMO Partner
• 6.6. Future Perspective

7. MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. ADC Contract Manufacturers: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Type of ADC Manufacturing Service Offered
  • 7.2.5. Analysis by Type of Additional Service Offered
  • 7.2.6. Analysis by Scale of Operation
  • 7.2.7. Analysis by Location of Manufacturing Facility

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key Parameters
• 8.3. Methodology
• 8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
  • 8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
  • 8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
  • 8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
• 8.5. Capability Benchmarking of top ADC Contract Manufacturers

9. COMPANY PROFILES: ADC CONTRACT MANUFACTURERS

• 9.1. Chapter Overview
• 9.2. MabPlex
  • 9.2.1. Company Overview
  • 9.2.2. ADC Related Services
  • 9.2.3. Manufacturing Facilities
  • 9.2.4. Recent Developments and Future Outlook
• 9.3. Lonza
• 9.4. Abzena
• 9.5. GBI
• 9.6. CARBOGEN AMICS
• 9.7. Millipore Sigma
• 9.8. WuXi Biologics
• 9.9. Catalent Pharma Solutions
• 9.10. Cerbios-Pharma
• 9.11. Formosa Laboratories
• 9.12. Sterling Pharma Solutions
• 9.13. Piramal Pharma Solutions
• 9.14. AbbVie Contract Manufacturing

10. RECENT EXPANSIONS

• 10.1. Chapter Overview
• 10.2. ADC Contract Manufacturers: Recent Expansions
  • 10.2.1. Analysis by Year of Expansion
  • 10.2.2. Analysis by Type of Expansion
  • 10.2.3. Analysis by Purpose of Expansion
  • 10.2.4. Analysis by Type of Facility
  • 10.2.5. Analysis by Scale of Operation
  • 10.2.6. Analysis by Location of Expanded Facility
  • 10.2.7. Most Active Players: Analysis by Number of Expansions

11. PARTNERSHIPS AND COLLABORATIONS

• 11.1. Chapter Overview
• 11.2. Partnership Models
• 11.3. ADC Contract Manufacturers: Partnerships and Collaborations
  • 11.3.1. Analysis by Year of Partnership
  • 11.3.2. Analysis by Type of Partnership
  • 11.3.3. Analysis by Scale of Operation
  • 11.3.4. Most Active Players: Analysis by Number of Partnerships
  • 11.3.5. Analysis by Geography
    • 11.3.5.1. Intercontinental and Intracontinental Agreements
    • 11.3.5.2. Local and International Agreements

12. MAKE VERSUS BUY DECISION MAKING

• 12.1. Chapter Overview
• 12.2. Assumptions and Key Parameters
  • 12.2.1. Scenario 1
  • 12.2.2. Scenario 2
  • 12.2.3. Scenario 3
  • 12.2.4. Scenario 4
• 12.3. Concluding Remarks

13. VALUE CHAIN ANALYSIS

• 13.1. Chapter Overview
• 13.2. ADC Development Value Chain
• 13.3. Cost Distribution across the Value Chain
  • 13.3.1. Cost Associated with Antibody Manufacturing
  • 13.3.2. Cost Associated with Payload and Linker Manufacturing
  • 13.3.3. Cost Associated with Conjugation
  • 13.3.4. Cost Associated with Fill / Finish

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. ADC Manufacturing: Global Installed Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Location of Headquarters
  • 14.3.3. Analysis by Location of Manufacturing Facility
    • 14.3.3.1. Analysis by Region
    • 14.3.3.2. Analysis by Country
  • 14.3.4. Analysis by Key Players

15. CASE STUDY: ADC THERAPEUTICS MARKET OVERVIEW

• 15.1. Chapter Overview
• 15.2. ADC Therapeutics: Therapies Pipeline
  • 15.2.1. Analysis by Status of Development
  • 15.2.2. Analysis by Target Disease Indication
  • 15.2.3. Analysis by Therapeutic Area
  • 15.2.4. Analysis by Line of Treatment
  • 15.2.5. Analysis by Dosing Frequency
  • 15.2.6. Analysis by Type of Therapy
  • 15.2.7. Analysis by Target Antigen
  • 15.2.8. Analysis by Antibody Isotype
  • 15.2.9. Analysis by Payload / Cytotoxin / Warhead
  • 15.2.10. Analysis by Type of Payload
  • 15.2.11. Analysis by Linker
  • 15.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
• 15.3. Antibody Drug Conjugates: Therapies to Watch
• 15.4. Concluding Remarks

16. CLINICAL TRIAL ANALYSIS

• 16.1. Chapter Overview
• 16.2. Scope and Methodology
• 16.3. Antibody Drug Conjugates: Clinical Trial Analysis
  • 16.3.1. Analysis by Trial Registration Year
  • 16.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
  • 16.3.3. Analysis by Trial Phase
  • 16.3.4. Analysis of Number of Patients Enrolled by Trial Phase
  • 16.3.5. Analysis by Trial Status
  • 16.3.6. Analysis by Trial Registration Year and Trial Status
  • 16.3.7. Analysis of Number of Patients Enrolled by Trial Status
  • 16.3.8. Analysis by Patient Gender
  • 16.3.9. Analysis by Study Design
    • 16.3.9.1. Analysis by Type of Allocation
    • 16.3.9.2. Analysis by Type of Intervention Model
    • 16.3.9.3. Analysis by Type of Masking
    • 16.3.9.4. Analysis by Trial Purpose
  • 16.3.10. Analysis by Type of Sponsor / Collaborator
  • 16.3.11. Leading Industry Players: Analysis by Number of Clinical Trials
  • 16.3.12. Leading Non-Industry Players: Analysis by Number of Clinical Trials
  • 16.3.13. Analysis by Geography
    • 16.3.13.1. Analysis of Clinical Trials by Geography
    • 16.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
    • 16.3.13.3. Analysis of Patients Enrolled by Geography and Trial Status

17. LIKELY PARTNER ANALYSIS

• 17.1. Chapter Overview
• 17.2. Scoring Criteria and Key Assumptions
• 17.3. Scope and Methodology
• 17.4. Potential Strategic Partners based in North America
  • 17.4.1. Most Likely Partners
  • 17.4.2. Likely Partners
  • 17.4.3. Least Likely Partners
• 17.5. Potential Strategic Partners based in Europe
  • 17.5.1. Most Likely Partners
  • 17.5.2. Likely Partners
  • 17.5.3. Least Likely Partners
• 17.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
  • 17.6.1. Most Likely Partners
  • 17.6.2. Likely Partners
  • 17.6.3. Least Likely Partners

18. ADC THERAPEUTICS: DEMAND ANALYSIS

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. ADC Therapeutics: Global Annual Demand
  • 18.3.1. ADC Therapeutics: Annual Commercial Demand
    • 18.3.1.1. Analysis by Target Indication
    • 18.3.1.2. Analysis by Antibody Origin
    • 18.3.1.3. Analysis by Antibody Isotype
    • 18.3.1.4. Analysis by Type of Payload
    • 18.3.1.5. Analysis by Type of Linker
    • 18.3.1.6. Analysis by Key Geographical Regions
  • 18.3.2. ADC Therapeutics: Annual Clinical Demand
    • 18.3.2.1. Analysis by Phase of Development
    • 18.3.2.2. Analysis by Target Indication
    • 18.3.2.3. Analysis by Antibody Origin
    • 18.3.2.4. Analysis by Antibody Isotype
    • 18.3.2.5. Analysis by Type of Payload
    • 18.3.2.6. Analysis by Type of Linker
    • 18.3.2.7. Analysis by Key Geographical Regions

19. REGIONAL CAPABILITY ANALYSIS

• 19.1. Chapter Overview
• 19.2. Assumptions and Key Parameters
• 19.3. ADC Contract Manufacturing Capabilities in North America
• 19.4. ADC Contract Manufacturing Capabilities in Europe
• 19.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

20. ATTRACTIVENESS COMPETITIVENESS MATRIX

• 20.1. Chapter Overview
• 20.2. AC Matrix: Overview
  • 20.2.1. Strong Business Segments
  • 20.2.2. Average Business Segments
  • 20.2.3. Weak Business Segments
• 20.3. AC Matrix: Analytical Methodology
• 20.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
  • 20.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
  • 20.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

21. MARKET IMPACT ANALYSIS

• 21.1. Chapter Overview
• 21.2. Market Drivers
• 21.3. Market Restraints
• 21.4. Market Opportunities
• 21.5. Market Challenges
• 21.6. Conclusion

22. GLOBAL ADC CONTRACT MANUFACTURING MARKET

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Global ADC Therapeutics Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 22.3.1. Scenario Analysis
    • 22.3.1.1. Conservative Scenario
    • 22.3.1.2. Optimistic Scenario
• 22.4. Key Market Segmentations

23. ADC CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. ADC Contract Manufacturing Market: Distribution by Scale of Operation
  • 23.3.1. ADC Contract Manufacturing Market for Clinical Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.3.2. ADC Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. ADC Contract Manufacturing Market: Distribution by Process Component
  • 24.3.1. ADC Contract Manufacturing Market for Antibodies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.2. ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.3. ADC Contract Manufacturing Market for Conjugation / Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.3.4. ADC Contract Manufacturing Market for Fill / Finish, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. ADC Contract Manufacturing Market: Distribution by Type of Payload
  • 25.3.1. ADC Contract Manufacturing Market for Tubulin Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.2. ADC Contract Manufacturing Market for Topoisomerase Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.3. ADC Contract Manufacturing Market for DNA Damaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

• 26.1. Chapter Overview
• 26.2. Key Assumptions and Methodology
• 26.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin
  • 26.3.1. ADC Contract Manufacturing Market for Humanized, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.2. ADC Contract Manufacturing Market for Chimeric, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.3. ADC Contract Manufacturing Market for Human, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

• 27.1. Chapter Overview
• 27.2. Key Assumptions and Methodology
• 27.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype
  • 27.3.1. ADC Contract Manufacturing Market for IgG1, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.2. ADC Contract Manufacturing Market for IgG4, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.3.3. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

• 28.1. Chapter Overview
• 28.2. Key Assumptions and Methodology
• 28.3. ADC Contract Manufacturing Market: Distribution by Target Indication
  • 28.3.1. ADC Contract Manufacturing Market for Solid Tumors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.3.2. ADC Contract Manufacturing Market for Hematological Malignancies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

• 29.1. Chapter Overview
• 29.2. Key Assumptions and Methodology
• 29.3. ADC Contract Manufacturing Market: Distribution by Type of Linker
  • 29.3.1. ADC Contract Manufacturing Market for Valine-citrulline, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.2. ADC Contract Manufacturing Market for SMCC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.3. ADC Contract Manufacturing Market for Hydrazone, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.4. ADC Contract Manufacturing Market for Maleimide, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.5. ADC Contract Manufacturing Market for Maleimidocaproyl, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.6. ADC Contract Manufacturing Market for Tetrapeptide-based Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.7. ADC Contract Manufacturing Market for Peptide Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.3.8. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 29.4. Data Triangulation and Validation

30. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 30.1. Chapter Overview
• 30.2. Key Assumptions and Methodology
• 30.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
  • 30.3.1. ADC Contract Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.1.1. ADC Contract Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.1.2. ADC Contract Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.1.3. ADC Contract Manufacturing Market in Rest of North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.3.2. ADC Contract Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.1. ADC Contract Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.2. ADC Contract Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.3. ADC Contract Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.4. ADC Contract Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.5. ADC Contract Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2.6. ADC Contract Manufacturing Market for Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.3.3. ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.1. ADC Contract Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.2. ADC Contract Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.3. ADC Contract Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.4. ADC Contract Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.5. ADC Contract Manufacturing Market for Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.6. ADC Contract Manufacturing Market for Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.7. ADC Contract Manufacturing Market for Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.8. ADC Contract Manufacturing Market for Chile, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.9. ADC Contract Manufacturing Market for Colombia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.10. ADC Contract Manufacturing Market for Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.11. ADC Contract Manufacturing Market for Kenya, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.12. ADC Contract Manufacturing Market for Peru, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.13. ADC Contract Manufacturing Market for South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.14. ADC Contract Manufacturing Market for Turkey, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.15. ADC Contract Manufacturing Market for Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3.16. ADC Contract Manufacturing Market for Other Countries, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
• 30.4. Data Triangulation and Validation

31. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

• 31.1. Chapter Overview
• 31.2. Key Assumptions and Methodology
• 31.3. Commercial ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
  • 31.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
  • 31.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
  • 31.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
  • 31.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
  • 31.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
  • 31.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
  • 31.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
• 31.4. Data Triangulation and Validation

32. CLINICAL ADC CONTRACT MANUFACTURING MARKET

• 32.1. Chapter Overview
• 32.2. Key Assumptions and Methodology
• 32.3. Clinical ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
  • 32.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates (Till 2035)
  • 32.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
  • 32.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
  • 32.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
  • 32.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
  • 32.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
  • 32.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
  • 32.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
• 32.4. Data Triangulation and Validation

33. CONCLUDING REMARKS

34. EXECUTIVE INSIGHTS

• 34.1. Chapter Overview
• 34.2. Company A
  • 34.2.1. Company Snapshot
  • 34.2.2. Interview Transcript: Business Development Manager
• 34.3. Company B
  • 34.3.1. Company Snapshot
  • 34.3.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
• 34.4. Company C
  • 34.4.1. Company Snapshot
  • 34.4.2. Interview Transcript: Chief Commercial Officer
• 34.5. Company D
  • 34.5.1. Company Snapshot
  • 34.5.2. Interview Transcript: Associate Scientist,
• 34.6. Company E
  • 34.6.1. Company Snapshot
  • 34.6.2. Interview Transcript: Former Director Corporate Development
• 34.7. Company F
  • 34.7.1. Company Snapshot
  • 34.7.2. Interview Transcript: Executive Director and Takashi Owa, Chief Innovation Officer
• 34.8. Company G
  • 34.8.1. Company Snapshot
  • 34.8.2. Interview Transcript: Former Chief Business Officer
• 34.9. Company H
  • 34.9.1. Company Snapshot
  • 34.9.2. Interview Transcript: Former Director of CDMO
• 34.10. Company I
  • 34.10.1. Company Snapshot
  • 34.10.2. Interview Transcript: Director, Business Development
• 34.11. Company J
  • 34.11.1. Company Snapshot
  • 34.11.2. Interview Transcript: Chief Executive Officer and Co-Founder
• 34.12. Company K
  • 34.12.1. Company Snapshot
  • 34.12.2. Interview Transcript: Former Site Head
• 34.13. Company L
  • 34.13.1. Company Snapshot
  • 34.13.2. Interview Transcript: Chief Executive Officer and Founder
• 34.14. Company M
  • 34.14.1. Company Snapshot
  • 34.14.2. Interview Transcript: Former Chief Executive Officer
• 34.15. Company N
  • 34.15.1. Company Snapshot
  • 34.15.2. Interview Transcript: Former Director, Business Development and Former Group Product Manager
• 34.16. Company O
  • 34.16.1. Company Snapshot
  • 34.16.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
• 34.17. Company P
  • 34.17.1. Company Snapshot
  • 34.17.2. Interview Transcript: Senior Director, Commercial Development and Marketing Strategy Bioconjugates

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION